The Role of Estrogen Receptors in Cardiovascular Disease.
Laila AryanDavid YounessiMichael ZargariSomanshu BanerjeeJacqueline AgopianShadie RahmanReza BornaGregoire RuffenachSoban UmarMansoureh EghbaliPublished in: International journal of molecular sciences (2020)
Cardiovascular Diseases (CVDs) are the leading cause of death globally. More than 17 million people die worldwide from CVD per year. There is considerable evidence suggesting that estrogen modulates cardiovascular physiology and function in both health and disease, and that it could potentially serve as a cardioprotective agent. The effects of estrogen on cardiovascular function are mediated by nuclear and membrane estrogen receptors (ERs), including estrogen receptor alpha (ERα), estrogen receptor beta (ERβ), and G-protein-coupled ER (GPR30 or GPER). Receptor binding in turn confers pleiotropic effects through both genomic and non-genomic signaling to maintain cardiovascular homeostasis. Each ER has been implicated in multiple pre-clinical cardiovascular disease models. This review will discuss current reports on the underlying molecular mechanisms of the ERs in regulating vascular pathology, with a special emphasis on hypertension, pulmonary hypertension, and atherosclerosis, as well as in regulating cardiac pathology, with a particular emphasis on ischemia/reperfusion injury, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction.
Keyphrases
- estrogen receptor
- cardiovascular disease
- heart failure
- pulmonary hypertension
- ischemia reperfusion injury
- left ventricular
- blood pressure
- type diabetes
- cardiovascular events
- healthcare
- cardiovascular risk factors
- public health
- copy number
- pulmonary artery
- pulmonary arterial hypertension
- metabolic syndrome
- risk assessment
- gene expression
- fluorescent probe
- living cells
- social media
- coronary artery disease
- dna binding
- acute heart failure
- human health
- single molecule